With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.167316-27-0,N-((1S,2S)-2-Amino-1,2-diphenylethyl)-4-methylbenzenesulfonamide,as a common compound, the synthetic route is as follows.
Under an atmosphere of argon, 134 mg (0.2 mmol) of [RuCl2(hexamethylbenzene)]2 147 mg (0.4 mmol) of (S,S)-TsDPEN, 183 mg (2.8 mmol ) of potassium hydroxide, 3 mL of methylene chloride, and 3 mL of water were placed in a 20 mL Schlenk tube and stirred at room temperature for 1 hour. The organic phase was washed with water several times, and sodium sulfate was then added to the organic phase to dry it. The organic phase was further dried with CaH2 and then filtered, the solvent was removed by distillation, and the residue was dried under vacuum. The violet crystals thus obtained were used directly in a reaction as a catalyst. By the same procedure as in Reference Example 1, Ru[(S,S)-Tsdpen] (1,2,3,4,5-pentamethylbenzene), Ru[(S,S)-Tsdpen] (1,2,4,5-tetramethylbenzene), Ru[(S,S)-Tsdpen] (1,3,5-trimethylbenzene), Ru[(S,S)-Tsdpen] (p-cymene), and Ru[(S,S)-Msdpen] (hexamethylbenzene) were synthesized. Furthermore, RuH[(R,R)-Tsdpen] (1,3,5-trimethylbenzene) was synthesized by carrying out the reaction of Reference Example 1 in 2-propanol.
167316-27-0, As the paragraph descriping shows that 167316-27-0 is playing an increasingly important role.
Reference£º
Patent; Kanto Kagaku Kabushiki Kaisha; EP1439159; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI